Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Biological: Benralizumab, Biological: Placebo to Mepolizumab
(Nucala)		[2] Benralizumab,
Mepolizumab (Nucala)		[2] Mepolizumab (Nucala),
Benralizumab 💬 		[2] IL5,
IL5RA 💬 		[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 44 💬
2Biological: Mepolizumab, Biological: Placebo to Benralizumab
(Nucala)		[2] Benralizumab,
Mepolizumab (Nucala)		[2] Mepolizumab (Nucala),
Benralizumab 💬 		[2] IL5,
IL5RA 💬 		[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 44 💬
3Mepolizumab
(Nucala)		[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[4] 44, 45, 98, 162 💬
4Mepolizumab (a-IL-5 antibody)
(Nucala)		[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 162 💬
5Mepolizumab 100 mg
(Nucala)		[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98 💬
6Mepolizumab 300 mg
(Nucala)		[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98 💬
7NUCALA[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬
8Nucala 100 mg powder for solution for injection[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬
9NUCALA®[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 44 💬
10SB-240563 (mepolizumab)
(Nucala)		[1] Mepolizumab (Nucala)[1] Mepolizumab (Nucala) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬